La cadena de opciones muestra datos clave de las opciones de acciones de RAPT Therapeutics a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para RAPT Therapeutics..

RAPT Therapeutics (NASDAQ:RAPT) Bolsa, Cadena de Opciones

RAPT Therapeutics

RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.

RAPT Therapeutics Inc

RAPT upgraded at H.C. Wainwright on China licensing deal

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include:&nbsp...

Biotech Alert: Searches spiking for these stocks today

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1. STOCK NEWS: Nippon Steel (NPSCY) pushes out expect...

Wedbush hikes Apple target to high on Street: Morning Buzz

US stock futures and Treasuries dropped as muted trading resumed after the Christmas holiday, with investors looking to initial jobless claims data and a government bond auction later on Thursday.

Futures Slide As Bond Yields Jump To 6 Month High

Notable analyst calls this week: FREYR Battery, Apple and ServiceNow among top picks

RAPT Therapeutics (RAPT) announced the appointment of Lori Lyons-Williams as chair of its board of directors, succeeding William Rieflin, who stepp...

Rapt Therapeutics appoints Lyons-Williams as chair of board of directors

The latest update is out from RAPT Therapeutics ( ($RAPT) ). RAPT Therapeutics announced that William Rieflin has resigned from its Board of Direct...

RAPT Therapeutics Announces Leadership Changes and Realignment

RAPT Therapeutics ( ($RAPT) ) has provided an announcement. RAPT Therapeutics announced plans to initiate Phase 2b trials for RPT904 in food allerg...

RAPT Therapeutics Plans Phase 2b Trials for RPT904

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on RAPT Therapeutics (RAPT – Research Report), GE Healt...

Analysts Are Bullish on Top Healthcare Stocks: RAPT Therapeutics (RAPT), GE Healthcare Technologies Inc (GEHC)

16:59 EST Rapt Therapeutics (RAPT) files to sell 176.45M shares of common stock for holders Published first on TheFly – the ultimate source for rea...

Rapt Therapeutics files to sell 176.45M shares of common stock for holders

AAPL

ACRS

AEHR

AMZN

APOG

AVXL

BABA

CALM

COST

DASH

DLVHF

EVER

FGEN

FREY

GEHC

GOOG

GOOGL

HGTY

IRTC

KULR

LAES

MSFT

MSTR

NFLX

NISTF

NNDM

NPSCY

ONCY

PBYI

PHIO

PVLA

RAPT

RDDT

RHHBF

RHHBY

RIOT

SLGL

SSNLF

SVNDF

SVNDY

UBER

Press Releases

RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer Patients

Earnings

RAPT Therapeutics Reports First Quarter 2024 Financial Results

News

Legal

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against RAPT Therapeutics, Inc. and Encourages Investors to Contact the Firm

RAPT Therapeutics Reports Second Quarter 2024 Financial Results

Based on Recent FDA Feedback RAPT Therapeutics Stops Zelnecirnon Program Following Clinical Hold Due to Single SAE of Severe Liver Injury

RAPT Therapeutics Reports Third Quarter 2024 Financial Results

RAPT Therapeutics and Shanghai Jemincare Pharmaceutical Announce Exclusive License Agreement for Novel Long-Acting anti-IgE Antibody

RAPT Therapeutics Announces $150 Million Private Placement

Management

RAPT Therapeutics Names Lori Lyons-Williams Chair of the Company's Board of Directors

RAPT Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

CTNM

Acrivon Therapeutics, Inc. - Common Stock

Acrivon Therapeutics

Actuate Therapeutics, Inc. - Common stock

Actuate Therapeutics

Adaptimmune Therapeutics plc - American Depositary Shares

Adaptimmune Therapeutics

Alector

Biomea Fusion

Coherus BioSciences

Cellectis S.A. - American Depositary Shares

Cellectis

Fate Therapeutics

Genelux

Innate Pharma S.A. - American Depositary Shares

Innate Pharma

Invizyne Technologies Inc. - Common Stock

Invizyne Technologies

Kyverna Therapeutics, Inc. - Common Stock

Kyverna Therapeutics

Lexeo Therapeutics

Lyell Immunopharma

Nanobiotix

Nkarta

Puma Biotechnology

Palvella Therapeutics, Inc. - Common Stock

Palvella Therapeutics

Sutro Biopharma

Protara Therapeutics, Inc. - Common Stock

Protara Therapeutics

TScan Therapeutics

Instil Bio

TriSalus Life Sciences, Inc. - Common Stock

TriSalus Life Sciences

Vor Biopharma

Vaxart

HC Wainwright & Co.

Wells Fargo

Barclays

Leerink Partners

Comments

RAPT Therapeutics

RAPT Therapeutics (RAPT) Opciones

RAPT Therapeutics (NASDAQ:RAPT) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL